While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...
Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...
The appeal court set Empire Company Limited et al v. Attorney General of Canada, A-192-24 on Feb. 12, Wednesday. This appeal ...
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
Piper Sandler, a well-known investment firm, increased its price target on shares of Amgen (NASDAQ:AMGN) to $329.00, up from the previous target of $310.00. The firm has maintained its Overweight ...
Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...
Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...
The Government of Canada is making a major push into genomics, investing $175.1 million to turn cutting-edge research into real-world breakthroughs in healthcare, agriculture, and clean technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback